GlassScriptPhysician profile
Muralidhar Beeram
NPI 1265426282
$90,888.19
in general payments reported to CMS, 2019-2025
72 companies · $4,261 in 2025
The $4,261 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $5,028 · 2021: $2,668 · 2022: $6,738 · 2023: $3,205 · 2024: $9,595 · 2025: $4,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,270 · Travel and Lodging: $1,508 · Consulting Fee: $800 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,322.02 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,270.00 |
| Travel and Lodging | $1,508.00 |
| Consulting Fee | $800.00 |
| Education | $161.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39,254.79 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $33,047.24 | 2019-2025 | Polivy, Columvi, Lunsumio |
| E.R. Squibb & Sons, L.L.C. | $6,513.16 | 2019-2025 | Opdualag, Opdivo, Augtyro |
| Novartis Pharmaceuticals Corporation | $1,446.97 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,286.97 | 2019-2025 | Tagrisso, Calquence, Enhertu |
| Janssen Biotech, INC. | $927.71 | 2019-2025 | Tecvayli, Rybrevant, Balversa |
| Eli Lilly and Company | $800.00 | 2020-2023 | |
| Daiichi Sankyo INC. | $443.28 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $411.47 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $364.20 | 2023-2025 | Fruzaqla, Iclusig, Ninlaro |
| Eisai INC. | $359.08 | 2019-2025 | |
| Genzyme Corporation | $355.08 | 2020-2025 | |
| Incyte Corporation | $329.46 | 2019-2025 | Jakafi, Monjuvi, Niktimvo |
| Celgene Corporation | $322.68 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Lilly USA, LLC | $285.01 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $282.90 | 2023-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $245.89 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $230.56 | 2024 | Precisetumor |
| Regeneron Healthcare Solutions, INC. | $212.59 | 2019-2025 | Libtayo |
| Astellas Pharma US INC | $211.48 | 2019-2025 | Vyloy, Xospata, Padcev |
| Karyopharm Therapeutics INC. | $202.23 | 2020-2025 | Xpovio |
| Puma Biotechnology, INC. | $201.61 | 2019-2025 | |
| Abbvie INC. | $199.47 | 2019-2025 | |
| Pharmaessentia USA Corporation | $187.10 | 2023-2025 | Besremi |
| Genmab U.S., INC. | $186.35 | 2023-2025 | Epkinly |
| Amgen INC. | $176.87 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Glaxosmithkline, LLC. | $173.23 | 2021-2025 | Ojjaara, Blenrep, Zejula |
| Seagen INC. | $151.20 | 2023-2025 | Tukysa, Padcev |
| Ipsen Biopharmaceuticals, INC | $136.50 | 2019-2025 | Onivyde, Somatuline Depot |
| Alexion Pharmaceuticals, INC. | $124.36 | 2019-2025 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $118.18 | 2022-2025 | Fotivda |
| Taiho Oncology, INC. | $114.87 | 2020-2025 | |
| Stemline Therapeutics INC. | $113.58 | 2023-2025 | Orserdu |
| Emd Serono, INC. | $112.13 | 2019-2025 | Bavencio |
| Array Biopharma INC | $104.28 | 2019-2025 | Mektovi, Braftovi, Xalkori |
| Adc Therapeutics America, INC. | $86.31 | 2022-2025 | |
| Sobi, INC | $74.14 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $73.62 | 2019 | |
| Rigel Pharmaceuticals, INC. | $73.33 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Deciphera Pharmaceuticals INC. | $62.45 | 2024-2025 | Qinlock, Romvimza |
| Immunocore Limited | $57.02 | 2023 | Kimmtrak |
| Morphosys, US INC. | $56.22 | 2022-2023 | Monjuvi |
| Blueprint Medicines Corporation | $47.81 | 2023-2025 | Ayvakit |
| Jazz Pharmaceuticals INC. | $46.08 | 2020-2024 | |
| Apellis Pharmaceuticals, INC. | $45.27 | 2025 | Empaveli |
| Medtronic USA, INC. | $45.26 | 2019 | |
| Kite Pharma, INC. | $41.62 | 2022-2023 | |
| Geron Corporation | $39.17 | 2025 | Rytelo |
| Agios Pharmaceuticals, INC. | $38.19 | 2023-2024 | Pyrukynd |
| Mirati Therapeutics, INC. | $36.78 | 2023 | Krazati |
| Servier Pharmaceuticals LLC | $33.44 | 2024 | |
| Beigene USA, INC. | $32.30 | 2025 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.64 | 2019 | |
| Exelixis INC. | $28.00 | 2021-2024 | Cabometyx |
| Fresenius Kabi USA, LLC | $27.82 | 2025 | Stimufend |
| Beone Medicines USA, INC. | $23.56 | 2025 | Tevimbra |
| Sun Pharmaceutical Industries INC. | $21.61 | 2025 | |
| Sirtex Medical INC | $21.41 | 2024 | Sir-Spheres Microspheres |
| Recordati_rare_diseases_inc. | $20.24 | 2023 | Sylvant |
| Springworks Therapeutics, INC. | $19.53 | 2024 | Ogsiveo |
| Azurity Pharmaceuticals, INC. | $19.36 | 2025 | Danziten |
| Fennec Pharmaceuticals, INC. | $18.38 | 2024 | Pedmark |
| Legend Biotech USA INC. | $18.13 | 2025 | Carvykti |
| Cti Biopharma Corp. | $17.97 | 2023 | Vonjo |
| Pharmacosmos Therapeutics INC. | $16.80 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.62 | 2019 | |
| Kyowa Kirin, INC. | $16.38 | 2024 | Poteligeo |
| Pharmacyclics LLC, An Abbvie Company | $15.54 | 2019 | |
| Foundation Medicine, INC. | $12.76 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.30 | 2019 | |
| Pharmaand Gmbh | $10.65 | 2025 | Rubraca |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,400.68 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muralidhar Beeram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.